Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 9:2022:9343514.
doi: 10.1155/2022/9343514. eCollection 2022.

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review

Semira Abdi Beshir  1 , A M Aadithsoorya  2 , Affana Parveen  3 , Sheron Sir Loon Goh  4 , Nadia Hussain  5 , Vineetha Bharathan Menon  6
Affiliations
Review

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review

Semira Abdi Beshir et al. Int J Alzheimers Dis. .

Abstract

Background: Aducanumab, a new monoclonal antibody that targets β-amyloid aggregates, has been granted conditional approval by the U.S. FDA for treatment of mild Alzheimer's disease (AD). The approval of this drug without a confirmed significant clinical impact has resulted in several debates.

Objective: In this narrative review, aducanumab approval-related controversy, the drug's pharmacokinetics and pharmacodynamic characteristics, evidence from the efficacy and safety trials of aducanumab, implications of the drug approval, and the future directions in the management of patients with AD are summarized.

Methods: Using relevant keywords, Google Scholar, Web of Science, and MEDLINE databases and manufacturer's website were searched.

Results: Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia. The drug however can cause amyloid-related imaging abnormalities. Due to modest impact on cognition, the use of this drug by patients with AD will most likely be limited. The manufacturer is required to run an extended phase IIIb trial to verify the benefit of this drug. Access to therapy requires a careful selection of patients and periodic monitoring to ensure the optimal use of the drug.

Conclusion: Despite the limitations, aducanumab is the first disease-modifying therapy approved for the treatment of AD. Aducanumab addresses a part of the pathogenesis of AD; therefore, drugs that can act on multiple targets are needed. In addition, the search for preventive strategies, validated plasma-based assays, and newer drugs for AD, which are effective, safe, convenient, and affordable, is vital.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic representation of aducanumab targets (soluble and insoluble beta-amyloid peptides); source [73].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Dementia . 2021. https://www.who.int/news-room/fact-sheets/detail/dementia .
    1. Dementia statistics. Alzheimer’s Disease International . 2021 https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
    1. Guo T., Zhang D., Zeng Y., Huang T. Y., Xu H., Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Molecular Neurodegeneration . 2020;15(1):1–37. doi: 10.1186/s13024-020-00391-7. - DOI - PMC - PubMed
    1. Chen Y. G. Research progress in the pathogenesis of Alzheimer’s disease. Chinese Medical Journal . 2018;131(13):1618–1624. doi: 10.4103/0366-6999.235112. - DOI - PMC - PubMed
    1. Plascencia-Villa G., Perry G. Alzheimer’s disease pharmacology. Reference Module in Biomedical Sciences . 2021 doi: 10.1101/2021.12.03.21267235. - DOI

LinkOut - more resources